This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioDelivery Sciences To Host Opioid Dependence Investor Event And Webcast On April 11, 2012

RALEIGH, N.C., April 5, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host a special event entitled " Treatment of Opioid Dependence: The Future Role of BEMA Buprenorphine/Naloxone" for investors and analysts on Wednesday, April 11, 2012 at 12:30 p.m. in New York City.  This event will include insightful discussion from medical experts with extensive experience in the management of opioid dependence and treatment with buprenorphine.

(Logo: )

In addition to presentations by independent experts in the management of opioid dependence, BDSI's management will speak about the clinical progress of BEMA Buprenorphine/Naloxone (BNX) for the potential treatment of opioid dependence. 

The expert presentations at this event will include:
  • "Understanding Opioid Dependence" by Gregory Sullivan, M.D. Board certified in Addiction Medicine and Medical Director of Parkway Medical Center in Birmingham, Alabama.  For twenty years, Dr. Sullivan has been actively involved in government and pharmaceutical research on the mechanism, biology and treatment of addiction and pain.
  • "Buprenorphine in the Successful Management of Opioid Dependence" by Aafaque Akhter, M.D. – Former instructor of Psychiatry at Harvard Medical School and Board certified in Psychiatry and Neurology.  Dr. Akhter is the founder and CEO of New England Counseling & Treatment Center, and Norton Health Care, which is one of the few clinics in the country exclusively focused on opiate addiction.

BDSI plans on initiating a pivotal pharmacokinetic study and the safety study for BNX in the third quarter of 2012.  Results of the pivotal pharmacokinetic study are anticipated to be available late in the third quarter of this year.  If positive, this would allow for an anticipated New Drug Application (NDA) filing in the first half of 2013.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.04%
FB $102.09 0.18%
GOOG $685.14 0.30%
TSLA $148.93 -1.00%
YHOO $26.88 0.45%


Chart of I:DJI
DOW 15,911.24 +251.06 1.60%
S&P 500 1,852.75 +23.67 1.29%
NASDAQ 4,306.1330 +39.2960 0.92%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs